The absolute bioavailability of oral vinorelbine in patients with solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 56, Issue 6, 2005, Pages 578-584

  Lush, Richard M ^a,b   McCune, Jeannine S ^c   Tetteh, Leticia ^a,b   Thompson, John A ^c   Mahany, J J ^a,b   Garland, Linda ^a,b,d   Suttle, A Benjamin ^e   Sullivan, Daniel M ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

^e GLAXOSMITHKLINE   (United States)

Author keywords

Bioavailability; Elderly; Pharmacokinetics; Vinorelbine

Indexed keywords

GELATIN; NAVELBINE;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BREATHING DISORDER; BURNING SENSATION; CALCULATION; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG CLEARANCE; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HUMAN; HYPESTHESIA; HYPOKALEMIA; INJECTION SITE REACTION; JAW DISEASE; LEUKOPENIA; LIQUID CHROMATOGRAPHY; MALE; MEASUREMENT; MOUTH INFECTION; MYALGIA; NAUSEA; NEUTROPENIA; PAIN; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SAFETY; SAMPLING; SOLID TUMOR; SORE THROAT; STOMATITIS; TACHYCARDIA; TANDEM MASS SPECTROMETRY; TASTE DISORDER; THROMBOCYTOPENIA; THRUSH; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; INTESTINAL ABSORPTION; MALE; MIDDLE AGED; NEOPLASMS; VINBLASTINE; VOMITING;

EID: 26444533541     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-005-1025-0     Document Type: Article

References (24)

1. Airoldi M, Pedani F, Succo G, Gabriele AM, Ragona R, Marchionatte S, Bumma C (2001) Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. Cancer 91(3):541-547
2. Bidoli P, Stani SC, De Candis D, Cortinovis D, Parra HS, Bajetta E (2001) Single-agent chemotherapy with vinorelbine for pretreated or metastatic squamous cell carcinoma of the esophagus. Tumori 87(5):299-302
3. Bonneterre J, Chevalier B, Focan C, Mauriac L, Piccart M (2001) Phase I and pharmacokinetic study of weekly oral therapy with vinorelbine in patients with advanced breast cancer (ABC). Ann Oncol 12(12):1683-1691
4. Burger RA, DiSaia PJ, Roberts JA, O'Rourke M, Gershenson DM, Homesley HD, Lightman SM, Barnes W, Moore DH, Monk BJ (1999) Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer. Gyn Oncol 72:148-153
5. Conroy T, Etienne PL, Adenis A, Wagener DJ, Paillot B, Francois E, Bedenne L, Jacob JH, Seitz JF, Bleiberg H, Van Pottelsberghe C, Van Glabbeke M, Delgado FM, Merle S, Wils J (1996) Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group. J Clin Oncol 14(1):164-170
6. Depierre A, Freyer G, Jassem J, Orfeuvre H, Ramlau R, Lemarie E, Koralewski P, Mauriac L, Breton JL, Delozier T, Trillet-Lenoir V (2001) Oral vinorelbine: feasibility and safety profile. Ann Oncol 12(12):1677-1681
7. Favre R, Delgado M, Besenval M et al (1989) Phase I trial of escalating doses of orally administered Navelbine (NVB): Part II - clinical results. Proc Am Soc Clin Onc 8:64
8. Freyer B, Delozier T, Lichinister M, Gedouin D, Bougnoux P, His P, Imadalou K, Trillet-Lenoir V (2003) Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 21(1):35-40
9. Gauvin A, Pinguet F, Culine S, Astre C, Gomeni R, Bressolle F (2000) Bayesian estimate of vinorelbine pharmacokinetic parameters in elderly patients with advanced metastatic cancer. Clin Cancer Res 6(7):2690-2695
10. Jassem J, Ramlau R, Karnicka-Mlodkowska H, Krawczyk K, Krzakowski M, Zatloukal P, Lemarie E, Hartmann W, Novakova L, O'Brien M, Depierr A (2001) A multicenter randomized phase II study of oral vs. intravenous vinorelbine in advanced non-small-cell lung cancer patients. Ann Oncol 12(10):1375-1381
11. Khayat D, Rixe O, Brunet R, Goupil A, Bugat R, Harousseau JL, Ifrah N, Puozzo C (2004) Pharmacokinetic Linearity of I.V. vinorelbine from an intra-patient dose escalation study design. Cancer Chemother Pharmacol 54(3):193-205
12. Krikorian A, Rahmani R, Bromet M, Bore P and Cano JP (1989) Pharmacokinetics and metabolism of Navelbine. Semin Oncol 16(2):21-25
13. Marty M, Fumoleau P, Adenis A, Rousseau Y, Merrouche Y, Robinet G, Senac I, Puozzo C (2001) Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol 12(11):1643-1649
14. Puozzo C, Gridelli C, Jaworski M (2002) Pharmacokinetics of Navelbine oral in elderly patients. Tumori 88(Suppl1):S75-S76
15. Rahmani R, Bore P, Cano JP et al (1989) Phase I trial of escalating doses of orally administered Navelbine (NVB): Part I - pharmacokinetics. Proc Am Soc Clin Onc 8:74
16. Rowinsky EK, Noe DA, Trump DL, Winer EP, Lucas VS, Wargin WA, Hohneker JA, Lubejko B, Sartorius SE, Ettinger DS, Donehower RC (1994) Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors. J Clin Oncol 12(9):1754-1763
17. Sorensen P, Hoyer M, Jakobsen A, Malmstrom H, Havsteen H, Bertelsen K (2001) Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma. Gynecol Oncol 81(1):58-62
18. Sorio R, Robieux I, Galligioni E, Freschi A, Colussi AM, Crivellari D, Saracchini S, Monfardini S (1997) Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer. Eur J Cancer 33(2):301-303
19. Tueni E, Dodion P, Piccart M, Wevy F, Kerger J, Delgado M (1990) A new oral Phase I trial with NAVELBINE (NVB) administered on a weekly schedule. J Cancer Res Clin Oncol (Suppl):16
20. Van Heugen JC, De Graeve J, Zorza G, Puozzo C (2001) New sensitive liquid chromatography method coupled with tandem mass spectrometric detection for the clinical analysis of vinorelbine and its metabolites in blood, plasma, urine and faeces. J Chromatogr A 926(1):11-20
21. Vokes EE, Rosenberg R, Jahanzeb M, Craig J, Gralla R, Belani C, Jones S, Bigley J, Hohneker J (1994) Oral vinorelbine (Navelbine) in the treatment of advanced non-small cell lung cancer: A preliminary report. Semin Oncol 21(Suppl):35-41
22. Vokes EE, Rosenberg RK, Jahanzeb M, Craig JB, Gralla RJ, Belani CP, Jones SE, Bigley JW, Hohneker JA (1995) Multicenter phase II study of weekly oral vinorelbine for stage IV non-small-cell lung cancer. J Clin Oncol 13(3):637-644
23. Wagner JG (1993) Pharmacokinetics for the Pharmaceutical Scientist Technomic Pub Co., p 88
24. Winer EP, Chu L, Spicer DV(1995) Oral vinorelbine (Navelbine) in the treatment of advanced breast cancer. Semin Oncol 22(2Suppl5):72-78